Every Form 4 that Progyny, Inc. (PGNY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PGNY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PGNY filings page.
Progyny, Inc. (PGNY) reported that its chief financial officer, Mark S. Livingston, had common shares withheld in early September 2026 to cover tax obligations from vesting equity awards. On September 3, 2026, 1,532 shares were withheld at $26.29 per share, and on September 2, 2026, 224 shares were withheld at $25.66 per share. A footnote states these were shares withheld for payment of withholding taxes upon the vesting of restricted stock units granted to him, rather than open-market sales.
Progyny, Inc. (PGNY) reported an insider equity tax event involving executive Allison Swartz, EVP and General Counsel. On August 28, 2026, Swartz had 1,352 shares of common stock withheld at $25.86 per share to pay withholding taxes upon vesting of restricted stock units. After this non-open-market, tax-withholding disposition, Swartz directly holds 81,026 shares of Progyny common stock.
Progyny, Inc. Chief Operating Officer Melissa B. Cummings reported insider transactions in Common Stock. On July 14, 2026, she executed an open-market sale of 2,244 shares at $31.60 per share under a pre-arranged Rule 10b5-1 trading plan. On the same date, 1,193 shares were disposed of to cover withholding taxes upon the vesting of restricted stock units. The tax-related share disposition was not an open-market sale.
Progyny, Inc. Chief Product Officer Geoffrey Clapp reported a routine share disposition related to taxes. On June 17, 2026, 819 shares of common stock were withheld at $26.60 per share to cover withholding taxes upon the vesting of restricted stock units. After this tax-withholding transaction, Clapp directly held 59,828 shares of Progyny common stock. This was not an open-market sale but an automatic share withholding to satisfy tax obligations tied to equity compensation.
Progyny, Inc. chief financial officer Mark S. Livingston reported small routine transactions in the company’s common stock. On June 4, 2026, he sold a total of 2,517 shares in open-market trades at $25.50 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. In addition, 1,421 shares were withheld on June 3 and June 4 to cover withholding taxes upon the vesting of restricted stock units. Following these transactions, Livingston directly holds 74,688 shares of Progyny common stock.
Progyny, Inc. executive vice president and general counsel Allison Swartz reported modest net selling of company common stock. She sold a total of 1,798 shares in open-market transactions on June 3–4, 2026 at prices around $25 per share, under a pre-arranged Rule 10b5-1 trading plan. Separate dispositions of 1,015 shares were made to cover withholding taxes upon the vesting of restricted stock units. After these transactions, she directly holds 82,378 shares of Progyny common stock.
Progyny, Inc. CEO Peter Anevski reported routine equity activity related to compensation. On Common Stock, 5,361 shares were disposed of at $25.12 per share as shares were withheld to pay withholding taxes upon the vesting of restricted stock units. Following this tax-withholding disposition, Anevski holds 811,472 shares of Progyny common stock directly, which include 1,111 shares acquired under the company’s 2019 Employee Stock Purchase Plan on January 30, 2026. He also reports an indirect holding of 1 share through PECO ANEVSKI 2020 SD LLC.
Progyny, Inc.’s Chief Financial Officer Mark S. Livingston reported routine equity transactions in company common stock. He sold 279 shares in an open-market trade at $26.20 per share, executed under a pre-arranged Rule 10b5-1 trading plan entered into on August 15, 2025.
In a separate entry, 158 shares were withheld at $26.20 per share to cover withholding taxes upon the vesting of restricted stock units granted to him. One line shows 78,905 shares owned after the tax-withholding entry, and another shows 78,626 shares owned after the sale.
Progyny director Scott Cheryl exercised stock options to acquire 14,667 shares of Common Stock at $13.00 per share, then sold 7,439 shares in an open-market transaction at about $26.39 per share. The company withheld 7,228 shares to cover tax obligations, and Cheryl now directly holds 19,772 shares.
Progyny, Inc. Chief Product Officer Geoffrey Clapp reported a combination of equity transactions in common stock. He exercised stock options to acquire 12,909 shares at $20.91 per share and sold 1,530 shares in an open-market transaction at $25.58 per share.
In a separate move, 11,379 shares were withheld to cover withholding taxes upon the vesting of restricted stock units granted to him. After these transactions, he directly holds 60,647 shares of Progyny common stock and 26,211 stock options that are scheduled to expire on March 16, 2035.
Progyny, Inc. executive vice president and general counsel Allison Swartz reported two transactions in company common stock on May 28, 2026. She completed an open-market sale of 2,398 shares at $25.46 per share under a pre-established Rule 10b5-1 trading plan. Separately, 1,352 shares were withheld to cover withholding taxes upon the vesting of restricted stock units, which is a non-market, compensation-related event. After these transactions, she directly owned 85,191 shares of Progyny common stock.
Progyny director Kevin K. Gordon reported an open-market sale and related share transfers. On 2026-05-27, he sold 5,500 shares of Progyny common stock at $24.99 per share, leaving 9,318 shares held directly. Separate restructuring transactions moved 2,526 shares from his direct ownership into the Kevin Gordon Revocable Declaration of Trust U/A/D 9/3/2013, which now holds 15,027 shares with Gordon serving as trustee.
Progyny, Inc. director Elizabeth D. Bierbower received equity-based compensation. She was granted 5,660 restricted stock units, each representing one share of common stock, and stock options covering 27,119 and 3,203 shares at an exercise price of $24.69. These awards vest on the earlier of May 21, 2027 or immediately before the company’s first annual stockholder meeting following the grant date, and the larger option grant replaces a $39,990 annual cash retainer for board and committee service.
Progyny, Inc. director Dean Lloyd H received new equity compensation consisting of common stock underlying restricted stock units and stock options. He was granted 6,792 shares of common stock underlying restricted stock units, bringing his direct common stock holdings to 26,519 shares.
He was also granted a stock option covering 28,203 shares of common stock at an exercise price of $24.69 per share, expiring on May 20, 2036. Both the restricted stock units and the option will vest on the earlier of May 21, 2027 or the calendar day immediately preceding Progyny’s first annual meeting of stockholders following the grant date, subject to his continued service.
Progyny, Inc. director Kevin K. Gordon reported equity awards and updated holdings. He received a grant of 6,792 shares of common stock in the form of restricted stock units (RSUs), each representing one share, at a stated price of $0.0000 per share. These RSUs vest on the earlier of May 21, 2027 or the calendar day immediately before Progyny’s first annual stockholders’ meeting following the grant date, subject to his continued service. Gordon also received a stock option for 30,373 shares of common stock at an exercise price of $24.6900 per share, vesting on the same schedule.
After these awards, he holds 14,818 shares of common stock directly, 12,501 shares indirectly through the Kevin Gordon Revocable Declaration of Trust where he serves as trustee, and 30,373 stock options scheduled to vest as described.
Progyny, Inc. director Roger C. Holstein reported equity compensation awards rather than market trades. He received 6,792 restricted stock units, each representing one share of common stock, and stock options covering 29,289 and 4,003 shares of common stock at an exercise price of $24.69 per share. These RSUs and options vest on the earlier of May 21, 2027 or the day before Progyny’s first annual stockholder meeting following the grant date, provided he continues serving as a director. After the RSU grant, Holstein directly holds 28,729 shares of common stock.
Progyny, Inc. director Jeffrey G. Park reported equity compensation awards in the form of restricted stock units and stock options. He received 7,924 RSUs, each representing one share of common stock, and his common stock holdings increased to 39,981 shares following the award.
On the same date, he was granted stock options covering 31,458 shares of common stock at a conversion price of $24.69 per share, issued in lieu of a $64,985 annual cash retainer for board and committee service, and additional options covering 5,205 shares. The RSUs and options vest on the earlier of May 21, 2027 or the day immediately preceding Progyny’s first annual meeting of stockholders following the grant date, subject to his continued service.
Progyny, Inc. director Payson Norman reported new equity awards and updated his holdings. On May 21, 2026, he received 5,660 restricted stock units, each representing one share of common stock. These RSUs vest on the earlier of May 21, 2027 or the day before the first annual shareholder meeting following the grant.
Norman was also granted stock options covering 27,119 shares of common stock at an exercise price of $24.69 per share, issued in lieu of a $39,990 cash retainer for board and committee service, plus an additional option for 3,203 shares at the same exercise price. These options vest on the same schedule as the RSUs.
After these awards, Norman directly holds 12,349 shares of Progyny common stock, along with the new options. Indirectly, 122,493 shares are held by The Norman C. and Melinda B. Payson Revocable Trust and 331,363 shares are held by EVO Eagle, LLC, where he shares voting and dispositive power.
Progyny, Inc. director Cheryl Scott received new equity compensation awards. She was granted 5,660 restricted stock units, each representing one share of common stock, and 27,119 stock options with an exercise price of $24.69 per share. Both the RSUs and options vest on the earlier of May 21, 2027 or the day before Progyny’s first annual stockholders’ meeting following the grant, subject to her continued board service. After these awards, she holds 19,772 shares of common stock directly, plus the 27,119 options.
Progyny, Inc. director Debra L. Morris reported routine equity compensation awards. She received 5,660 restricted stock units (RSUs), each representing one share of common stock, bringing her reported common stock holdings to 5,660 shares. The filing also shows two stock option grants covering 27,119 and 3,203 shares of common stock at an exercise price of $24.69 per share. According to the footnotes, these RSUs and options vest on the earlier of May 21, 2027 or the day before Progyny’s first annual stockholders’ meeting following the grant date, contingent on her continued board service. One option grant was issued in lieu of a $39,990 annual cash retainer for board and committee service.
Progyny, Inc. Chief Financial Officer Mark S. Livingston reported an open-market sale of 8,275 shares of common stock on May 20, 2026 at an average price of $25.50 per share. The sale was executed pursuant to a Rule 10b5-1 trading plan entered into on August 15, 2025, and Livingston now directly holds 79,063 shares.
Progyny, Inc. Chief Operating Officer Melissa B. Cummings reported an open-market sale of Common Stock. On May 19, 2026, she sold 9,578 shares at $25.00 per share. After this transaction, she directly holds 73,371 shares of Progyny common stock.
The filing notes that the shares were sold pursuant to a Rule 10b5-1 trading plan that was entered into on December 19, 2025, indicating the sale was pre-arranged under a preset plan rather than a discretionary trade based on recent developments.
Progyny, Inc. Chief Operating Officer Melissa B. Cummings had 4,172 shares of common stock withheld on April 14, 2026 to cover taxes on vesting restricted stock units. The shares were valued at $16.98 each for this tax-withholding transaction, which is not an open-market sale. After the withholding, she directly owns 82,949 shares of Progyny common stock.
Progyny, Inc. Chief Product Officer Geoffrey Clapp reported a routine share disposition related to taxes rather than an open-market trade. On March 17, 2026, 3,275 shares of common stock were withheld at $17.42 per share to cover withholding taxes upon the vesting of restricted stock units. Following this tax-withholding event, Clapp directly held 60,647 shares of Progyny common stock.
Progyny, Inc. executive vice president and general counsel Allison Swartz reported two stock transactions involving the company’s common stock. On March 4, 2026, 339 shares were withheld at $17.52 per share to cover withholding taxes upon the vesting of restricted stock units granted to her.
That same day, she sold 599 shares in an open-market transaction at $17.54 per share, executed under a pre-established Rule 10b5-1 trading plan entered into on May 13, 2025. After these transactions, she directly held 88,941 shares of Progyny common stock.
Progyny, Inc. chief financial officer Mark S. Livingston reported a small tax-related share disposition tied to equity compensation. On March 4, 2026, 339 shares of Progyny common stock were withheld at $17.52 per share to cover withholding taxes upon the vesting of his restricted stock units, rather than being sold in an open-market transaction. After this withholding, he directly owned 87,338 common shares of Progyny. This type of Form 4 event reflects routine administration of stock-based compensation rather than a discretionary buy or sell decision.
Progyny, Inc. reported that Chief Product Officer Geoffrey Clapp received new equity awards on March 2, 2026. He acquired stock-based incentives covering 51,373 shares of common stock underlying restricted stock units and a separate grant of 35,228 shares of common stock at no purchase price.
According to the grant terms, 33% of each award will vest on the first anniversary of the grant date, with the remaining portions vesting in quarterly installments through the third anniversary, subject to his continued service. These awards are described as annual merit grants under Progyny's 2019 Equity Incentive Plan.
Progyny, Inc. Chief Operating Officer Melissa B. Cummings reported new equity awards. She received a grant of stock options for 66,289 shares of common stock at no exercise cost in this report, recorded as a derivative security.
She also received 45,454 shares of common stock in the form of restricted stock units under Progyny’s 2019 Equity Incentive Plan. For each grant, 33% vests on the first anniversary of the March 2 grant date, with the remaining portion vesting in quarterly installments through the third anniversary, as long as she continues in service.
Progyny, Inc. EVP and General Counsel Allison Swartz reported multiple equity transactions in Progyny (PGNY) stock. On March 2, 2026, she received an annual merit grant of 28,409 shares of common stock and 41,430 stock options under the 2019 Equity Incentive Plan. These awards vest 33% on the first anniversary of the grant date, with the remainder vesting quarterly through the third anniversary, contingent on continued service. That same day, 1,551 shares were withheld at $17.69 per share to cover taxes on RSU vesting, and 2,199 shares were sold at $17.27 per share under a Rule 10b5-1 trading plan. On March 3, 2026, an additional 2,842 shares were withheld for taxes at $17.60 per share, and 500 shares and 4,157 shares were sold at $17.396 and $17.40 per share, respectively, also under the 10b5-1 plan. Following these transactions, she held 89,879 shares of common stock directly.
Progyny, Inc.’s chief financial officer Mark S. Livingston reported a mix of equity grants and related tax withholdings. He received a grant of 45,454 shares of common stock as restricted stock units and a separate stock option for 66,289 shares, both as annual merit awards under the 2019 Equity Incentive Plan. In connection with RSU vesting, the company withheld 4,579 shares on one date and 181 shares on another date at prices around $17.60–$17.69 per share to cover tax obligations, leaving him with 87,677 common shares directly owned after the larger withholding transaction.
Progyny, Inc. CEO Peter Anevski reported equity compensation and related tax withholding transactions. On March 2, 2026, he was granted 159,091 shares of common stock as restricted stock units and 232,011 stock options, both as annual merit grants under Progyny’s 2019 Equity Incentive Plan.
These awards vest over three years, with 33% vesting after one year and the remainder vesting quarterly, subject to continued service. On March 3, 2026, 17,611 common shares were withheld to cover taxes upon RSU vesting, leaving 816,833 common shares held directly. An additional 1 share is held indirectly through PECO ANEVSKI 2020 SD LLC.
Progyny, Inc. reported an insider stock transaction by its chief financial officer, Mark S. Livingston. On December 11, 2025, he sold 459 shares of Progyny common stock at $25.5 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 15, 2025. Following this transaction, he directly owns 46,983 shares of Progyny common stock.
Progyny, Inc.'s president reported a routine equity compensation-related share withholding. On 12/04/2025, 7,977 shares of common stock were withheld at $24.55 per share to pay withholding taxes triggered by the vesting of restricted stock units granted to the officer. After this transaction, the president directly beneficially owned 288,233 Progyny shares.
Progyny, Inc. (PGNY) reported an insider stock sale by its Chief Financial Officer. On 11/17/2025, the CFO sold 21,303 shares of Progyny common stock at a price of $25.50 per share, as shown in Table I of the filing. After this transaction, the CFO beneficially owns 48,358 shares of common stock in a direct capacity.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 15, 2025. These plans allow insiders to systematically sell shares according to preset instructions, helping separate personal liquidity decisions from day-to-day company developments.
Progyny, Inc. (PGNY) director reported an option exercise and a share transfer. On 11/14/2025, the reporting person exercised a stock option for 36,224 shares of common stock at $1.45 per share, paying the exercise price in cash and holding all shares received, with no shares sold in connection with the exercise.
On 11/18/2025, the reporting person transferred 50,265 shares held directly to The Norman C. and Melinda B. Payson Revocable Trust for no consideration, reported as a gift. Following these transactions, the person held common stock directly and also indirectly through the revocable trust and through EVO Eagle, LLC, over which the reporting person shares voting and dispositive power.
Progyny, Inc. (PGNY) disclosed that its Chief Executive Officer and director purchased 79,500 shares of common stock on 11/13/2025. The shares were bought at a weighted average price of $24.288 per share, in multiple trades at prices ranging from $23.73 to $24.52. Following this transaction, the reporting person beneficially owns 680,251 shares directly and an additional share indirectly through PECO ANEVSKI 2020 SD LLC. The filing notes that the purchase was made to offset a tax withholding obligation arising from the net settlement of performance stock units reported the same day.
Progyny, Inc. (PGNY) Form 4: The Executive Chairman and director reported the vesting and settlement of performance stock units. On 11/10/2025, 41,500 PSUs granted on January 1, 2022 were settled into common stock after the Compensation Committee certified performance on 10/31/2025.
To cover withholding taxes upon vesting, 21,286 shares were withheld at $22.37. Following these transactions, the reporting person directly beneficially owns 240,633 shares. These entries reflect equity award settlement and related tax withholding, not an open‑market purchase or sale.
Progyny, Inc. (PGNY) reported an insider equity transaction by its Chief Executive Officer and director. The filing shows the settlement of previously earned performance stock units and related tax withholding.
On November 10, 2025, the reporting person acquired 125,000 shares of common stock at $0 upon settlement of PSUs that vested on October 31, 2025, after certification of performance. On the same date, 63,813 shares were withheld to cover taxes at a price of $22.37 per share. Following these transactions, the filer beneficially owned 600,751 shares directly, plus 1 share held indirectly.
Progyny, Inc. director and Executive Chairman David J. Schlanger reported a sale of 1,893 shares of Progyny common stock on 10/01/2025 at a price of $21.52 per share. After the transaction, the filing shows he beneficially owns 220,419 shares, held directly. The filing states the shares sold were withheld to cover taxes upon the vesting of restricted stock units granted to the reporting person. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Progyny director and Chief Executive Officer Peter Anevski reported an insider transaction dated 10/01/2025. The Form 4 shows 7,977 shares of Progyny common stock were disposed of at a price of $21.52 per share, with the filer retaining beneficial ownership of 539,564 shares following the transaction. The filing explains the sale resulted from shares withheld to cover taxes on vested restricted stock units and notes the remaining reportable shares are held directly by PECO ANEVSKI 2020 SD LLC. The Form 4 was signed by an attorney-in-fact on 10/02/2025.